Quick Answer
Sarepta Therapeutics, Inc. reported Net Income of -$713.41 million for fiscal year 2025.
Sarepta Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$713.41M | -403.3% |
| 2024 | $235.24M | +143.9% |
| 2023 | -$535.98M | +23.8% |
| 2022 | -$703.49M | -68.0% |
| 2021 | -$418.78M | +24.4% |
| 2020 | -$554.13M | +22.5% |
| 2019 | -$715.08M | -97.6% |
| 2018 | -$361.92M | -614.0% |
| 2017 | -$50.69M | +81.0% |
| 2016 | -$267.26M | -21.5% |
| 2015 | -$220.03M | -62.0% |
| 2014 | -$135.79M | -21.3% |
| 2013 | -$111.98M | +7.7% |
| 2012 | -$121.29M | -5132.4% |
| 2011 | -$2.32M | +92.8% |
| 2010 | -$32.18M | -27.9% |
| 2009 | -$25.16M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$179.95M | -635.4% | -191.4% |
| June 30, 2025 | $196.89M | +2947.9% | +144.0% |
| March 31, 2025 | -$447.51M | -1339.0% | -1431.4% |
| September 30, 2024 | $33.61M | +182.1% | +420.3% |
| June 30, 2024 | $6.46M | +127.0% | -82.1% |
| March 31, 2024 | $36.12M | +107.0% | +188.2% |
| September 30, 2023 | -$40.94M | +84.1% | -71.0% |
| June 30, 2023 | -$23.94M | +89.7% | +95.4% |
- Sarepta Therapeutics, Inc. showed a decrease of -403.3% in Net Income compared to the prior fiscal year.
- Over the 2009–2025 period, Sarepta Therapeutics, Inc.’s net income has declined by 2735.6% (from -$25.16 million to -$713.41 million).
- The most recent figure is from Sarepta Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 2, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: